GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Price-to-Owner-Earnings

Trinity Biotech (Trinity Biotech) Price-to-Owner-Earnings

: (As of Today)
View and export this data going back to 1995. Start your Free Trial

As of today (2024-04-20), Trinity Biotech's share price is $1.8054. Trinity Biotech does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Trinity Biotech's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Trinity Biotech was 393.05. The lowest was 123.41. And the median was 133.85.


TRIB's Price-to-Owner-Earnings is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 24.4
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-20), Trinity Biotech's share price is $1.8054. Trinity Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.74. Therefore, Trinity Biotech's PE Ratio for today is At Loss.

As of today (2024-04-20), Trinity Biotech's share price is $1.8054. Trinity Biotech's EPS without NRI for the trailing twelve months (TTM) ended in was $-3.63. Therefore, Trinity Biotech's PE Ratio without NRI for today is At Loss.

During the past 13 years, Trinity Biotech's highest PE Ratio without NRI was 103.87. The lowest was 0.00. And the median was 29.62.


Trinity Biotech Price-to-Owner-Earnings Historical Data

The historical data trend for Trinity Biotech's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Trinity Biotech Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Diagnostics & Research subindustry, Trinity Biotech's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech Price-to-Owner-Earnings Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's Price-to-Owner-Earnings falls into.



Trinity Biotech Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Trinity Biotech's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.8054/-3.93
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Trinity Biotech  (NAS:TRIB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Trinity Biotech Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Trinity Biotech (Trinity Biotech) Business Description

Traded in Other Exchanges
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.